An Open Label, Non-randomized Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 05 Oct 2016
At a glance
- Drugs WNT 974 (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 29 Sep 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 14 Jun 2016 Planned initiation date changed from 1 Apr 2016 to 1 Jun 2016.
- 25 Mar 2016 Planned initiation date changed from 1 Feb 2016 to 1 Apr 2016 as reported by ClinicalTrials.gov.